Impact of treosulfan exposure on early and long-term clinical outcome in pediatric allogeneic HSCT recipients: a prospective multicenter study.

[1]  M. Spohn,et al.  Influence of anti-thymocyte globulin plasma levels on outcome parameters in stem cell transplanted children. , 2020, International immunopharmacology.

[2]  G. Lucchini,et al.  Proposed Therapeutic Range of Treosulfan in Reduced Toxicity Pediatric Allogeneic Hematopoietic Stem Cell Transplant Conditioning: Results From a Prospective Trial , 2019, Clinical pharmacology and therapeutics.

[3]  H. Guchelaar,et al.  Population pharmacokinetics of treosulfan in paediatric patients undergoing hematopoietic stem cell transplantation , 2019, British journal of clinical pharmacology.

[4]  P. Veys,et al.  Population Pharmacokinetics of Alemtuzumab (Campath) in Pediatric Hematopoietic Cell Transplantation: Towards Individualized Dosing to Improve Outcome , 2019, Clinical Pharmacokinetics.

[5]  T. Bauters,et al.  Thiotepa-induced cutaneous toxicity in pediatric patients: Case report and implementation of preventive care guidelines , 2018, Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners.

[6]  J. Panetta,et al.  Pharmacokinetics and Pharmacodynamics of Treosulfan in Patients With Thalassemia Major Undergoing Allogeneic Hematopoietic Stem Cell Transplantation , 2018, Clinical pharmacology and therapeutics.

[7]  H. Guchelaar,et al.  High interpatient variability of treosulfan exposure is associated with early toxicity in paediatric HSCT: a prospective multicentre study , 2017, British journal of haematology.

[8]  J. Wachowiak,et al.  Population pharmacokinetics of treosulfan and development of a limited sampling strategy in children prior to hematopoietic stem cell transplantation , 2017, European Journal of Clinical Pharmacology.

[9]  V. Ivaturi,et al.  Pharmacokinetics and Model-Based Dosing to Optimize Fludarabine Therapy in Pediatric Hematopoietic Cell Transplant Recipients. , 2017, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[10]  F. Główka,et al.  Kinetic and Mechanistic Study of the pH-Dependent Activation (Epoxidation) of Prodrug Treosulfan Including the Reaction Inhibition in a Borate Buffer. , 2017, Journal of pharmaceutical sciences.

[11]  C. van Kesteren,et al.  Association between anti-thymocyte globulin exposure and survival outcomes in adult unrelated haemopoietic cell transplantation: a multicentre, retrospective, pharmacodynamic cohort analysis. , 2017, The Lancet. Haematology.

[12]  A. Egberts,et al.  Association of busulfan exposure with survival and toxicity after haemopoietic cell transplantation in children and young adults: a multicentre, retrospective cohort analysis. , 2016, The Lancet. Haematology.

[13]  A. Schulz,et al.  Treosulfan-based conditioning for allogeneic HSCT in children with chronic granulomatous disease: a multicenter experience. , 2016, Blood.

[14]  Peter Shaw,et al.  Development and Validation of a High Pressure Liquid Chromatography-UV Method for the Determination of Treosulfan and Its Epoxy Metabolites in Human Plasma and Its Application in Pharmacokinetic Studies. , 2015, Journal of chromatographic science.

[15]  A. Gennery,et al.  Treosulfan-based conditioning regimens for allogeneic haematopoietic stem cell transplantation in children with non-malignant diseases , 2015, Bone Marrow Transplantation.

[16]  K. Washington,et al.  NIH Consensus development project on criteria for clinical trials in chronic graft-versus-host disease: II. The 2014 Pathology Working Group Report. , 2015, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[17]  J. Wachowiak,et al.  Pharmacokinetics of treosulfan and its active monoepoxide in pediatric patients after intravenous infusion of high-dose treosulfan prior to HSCT. , 2015, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[18]  P. Veys,et al.  Treosulfan-based conditioning regimens for allogeneic HSCT in children with acute lymphoblastic leukaemia , 2015, Annals of Hematology.

[19]  T. Torgerson,et al.  Treosulfan-based conditioning and hematopoietic cell transplantation for nonmalignant diseases: a prospective multicenter trial. , 2014, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[20]  H. Guchelaar,et al.  Pharmacokinetics of Treosulfan in Pediatric Patients Undergoing Hematopoietic Stem Cell Transplantation , 2014, Therapeutic drug monitoring.

[21]  C. Cancrini,et al.  HLA-haploidentical stem cell transplantation after removal of αβ+ T and B cells in children with nonmalignant disorders. , 2014, Blood.

[22]  N. Holford,et al.  Understanding dosing: children are small adults, neonates are immature children , 2013, Archives of Disease in Childhood.

[23]  A. Mastronuzzi,et al.  Allogeneic hematopoietic stem cell transplantation in thalassemia major: results of a reduced-toxicity conditioning regimen based on the use of treosulfan. , 2012, Blood.

[24]  J. Wachowiak,et al.  Pharmacokinetics of high-dose i.v. treosulfan in children undergoing treosulfan-based preparative regimen for allogeneic haematopoietic SCT , 2008, Bone Marrow Transplantation.

[25]  F. Appelbaum,et al.  Busulfan concentration and graft rejection in pediatric patients undergoing hematopoietic stem cell transplantation , 2002, Bone Marrow Transplantation.

[26]  J. Hartley,et al.  DNA alkylation and interstrand cross-linking by treosulfan , 1999, British Journal of Cancer.

[27]  E D Thomas,et al.  1994 Consensus Conference on Acute GVHD Grading. , 1995, Bone marrow transplantation.

[28]  F. Appelbaum,et al.  Regimen-related toxicity in patients undergoing bone marrow transplantation. , 1988, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.